Last Price
0.166
Today's Change
+0.006 (3.75%)
Day's Change
0.158 - 0.167
Trading Volume
42,190
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Michael S. Poirier Mr. Michael S. Poirier
Full Time Employees: 4 4
IPO Date: 2015-06-23 2015-06-23
CIK: 0001460702 0001460702
ISIN: US74754R2022 US74754R2022
CUSIP: 74754R103 74754R103
Beta: 0.07 0.07
Last Dividend: 0.00 0.00
Dcf Diff: 0.35 0.35
Dcf: -0.18 -0.18
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.